Literature DB >> 20855416

Demyelination versus remyelination in progressive multiple sclerosis.

Stephan Bramow1, Josa M Frischer, Hans Lassmann, Nils Koch-Henriksen, Claudia F Lucchinetti, Per S Sørensen, Henning Laursen.   

Abstract

The causes of incomplete remyelination in progressive multiple sclerosis are unknown, as are the pathological correlates of the different clinical characteristics of patients with primary and secondary progressive disease. We analysed brains and spinal cords from 51 patients with progressive multiple sclerosis by planimetry. Thirteen patients with primary progressive disease were compared with 34 with secondary progressive disease. In patients with secondary progressive multiple sclerosis, we found larger brain plaques, more demyelination in total and higher brain loads of active demyelination compared with patients with primary progressive disease. In addition, the brain density of plaques with high-grade inflammation and active demyelination was highest in secondary progressive multiple sclerosis and remained ~18% higher than in primary progressive multiple sclerosis after adjustments for other plaque types and plaque number (P<0.05). Conversely, the proportion of remyelinated shadow plaques (P<0.05) and the overall remyelination capacity (P<0.01) per brain were higher in primary, compared with secondary, progressive multiple sclerosis. By contrast, there were no group differences in the brain load or frequency of low-grade inflammatory plaques with slowly expanding demyelination. Spinal cord lesion loads and remyelination capacity were also comparable in the two patient groups. Remyelinated areas were more vulnerable than the normal-appearing white matter to new demyelination, including active demyelination in secondary progressive multiple sclerosis. 'Recurrent' slowly expanding demyelination, affecting remyelinated areas, and the load of slowly expanding demyelination correlated with incomplete remyelination in both groups. In turn, incomplete remyelination in the spinal cord correlated with higher disease-related disability (determined retrospectively; r = -0.53; P<0.05 for remyelination capacity versus disease severity). By contrast, such a correlation was not observed in the brain. We propose that regulatory and reparative properties could protect the white matter of the brain in patients with primary progressive multiple sclerosis. These patients may, thereby, be spared symptoms until the spinal cord is affected. By contrast, recurrent active demyelination of repaired myelin could explain why similar symptoms often develop in consecutive relapses in relapsing-remitting/secondary progressive multiple sclerosis. Our data also indicate that slowly expanding demyelination may irreparably destroy normal and repaired myelin, supporting the concept of slowly expanding demyelination as an important pathological correlate of clinical progression.

Entities:  

Mesh:

Year:  2010        PMID: 20855416     DOI: 10.1093/brain/awq250

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  98 in total

1.  Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions.

Authors:  Martina Absinta; Pascal Sati; Matthew Schindler; Emily C Leibovitch; Joan Ohayon; Tianxia Wu; Alessandro Meani; Massimo Filippi; Steven Jacobson; Irene C M Cortese; Daniel S Reich
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

Review 2.  The role of advanced magnetic resonance imaging techniques in primary progressive MS.

Authors:  Maria A Rocca; Martina Absinta; Massimo Filippi
Journal:  J Neurol       Date:  2011-08-04       Impact factor: 4.849

3.  Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia.

Authors:  Maria Karamita; Christopher Barnum; Wiebke Möbius; Malú G Tansey; David E Szymkowski; Hans Lassmann; Lesley Probert
Journal:  JCI Insight       Date:  2017-04-20

4.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Authors:  Melih Tutuncu; Junger Tang; Nuhad Abou Zeid; Nilufer Kale; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; Sean J Pittock; Istvan Pirko; B Mark Keegan; Claudia F Lucchinetti; John H Noseworthy; Moses Rodriguez; Brian G Weinshenker; Orhun H Kantarci
Journal:  Mult Scler       Date:  2012-06-26       Impact factor: 6.312

5.  Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2.

Authors:  Zhe Ji; Zhiqin Fan; Ying Zhang; Ronghuan Yu; Haihua Yang; Chenghua Zhou; Jia Luo; Zun-Ji Ke
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

6.  The flavonoid Baicalein attenuates cuprizone-induced demyelination via suppression of neuroinflammation.

Authors:  Miho Hashimoto; Shinji Yamamoto; Kensuke Iwasa; Kota Yamashina; Masaki Ishikawa; Kei Maruyama; Francesca Bosetti; Keisuke Yoshikawa
Journal:  Brain Res Bull       Date:  2017-09-15       Impact factor: 4.077

7.  Cortical remyelination: a new target for repair therapies in multiple sclerosis.

Authors:  Ansi Chang; Susan M Staugaitis; Ranjan Dutta; Courtney E Batt; Kathryn E Easley; Anthony M Chomyk; V Wee Yong; Robert J Fox; Grahame J Kidd; Bruce D Trapp
Journal:  Ann Neurol       Date:  2012-10-17       Impact factor: 10.422

Review 8.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 9.  Regulation of oligodendrocyte precursor migration during development, in adulthood and in pathology.

Authors:  Fernando de Castro; Ana Bribián; Maria Cristina Ortega
Journal:  Cell Mol Life Sci       Date:  2013-05-21       Impact factor: 9.261

Review 10.  Advanced MRI and staging of multiple sclerosis lesions.

Authors:  Martina Absinta; Pascal Sati; Daniel S Reich
Journal:  Nat Rev Neurol       Date:  2016-04-29       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.